Poly(ADP-ribose) polymerase (PARP) inhibition in renal cell carcinoma (RCC) is biologically plausible via synthetic lethality in tumors with impaired DNA-damage repair (DDR), notably BAP1 and other DDR lesions, yet clinical translation in metastatic RCC (mRCC) remains preliminary [6]. The gene discussed is PARP1; the disease is renal cell carcinoma.